Yeah, but the 'detractor' will tell you MSB will come and give them a tap on the shoulder on IP. They might bluster a bit, on legal advice, knowing there is ample IP differentiation to leave them ill advised to try anything other than a scary bluff. In reality, MSB is more likely to want to be a suitor itself than an antagonizer. But I am sure other parties will have jumped in far before MSB is ever making the revenues to enable such a purchase.
There is indeed a long way to go to successful commercialisation, as another detractor is keen to highlight. But that's the funny thing pf course with share mkts. They, admittedly less so in micro caps, tend to trade on a forward basis.
The Cheif Business Officer just confirmed ongoing talks continue with partnership prospects on yesterday's webinar. Excuse me if I take that at face value.
- Forums
- ASX - By Stock
- CYP
- CYP Price Target post MSB FDA approval.
CYP
cynata therapeutics limited
Add to My Watchlist
2.94%
!
16.5¢

CYP Price Target post MSB FDA approval., page-229
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $37.28M |
Open | High | Low | Value | Volume |
16.5¢ | 17.0¢ | 16.5¢ | $39.66K | 238.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 277684 | 16.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.5¢ | 14285 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 277684 | 0.165 |
6 | 607381 | 0.160 |
3 | 26451 | 0.155 |
3 | 115000 | 0.150 |
2 | 45937 | 0.140 |
Price($) | Vol. | No. |
---|---|---|
0.175 | 14285 | 1 |
0.180 | 108494 | 4 |
0.185 | 94565 | 3 |
0.190 | 133868 | 2 |
0.195 | 19300 | 1 |
Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |